News related to
risk

Abu Dhabi’s Festival of Health 2025 opened with government officials and community leaders urging citizens and residents to adopt healthier lifestyle habits as part of a broader strategy to transform public health culture across the emirate. The multi-week event, organised by the Department of Health – Abu Dhabi in partnership with the Abu Dhabi Public Health Centre, spans three weekends and more than 140 activities designed to engage families, young people, older adults and people of determination in movement, nutrition, sleep and mental wellbeing. The opening ceremony was attended by Mansoor Ibrahim Al Mansoori, Chairman of DoH, and Dr Rashed Al Suwaidi, Director General of ADPHC, underscoring the initiative’s profile within Abu Dhabi’s health agenda.

Officials expect more than 30,000 visitors to participate as the festival moves from Hudayriyat Island in Abu Dhabi city to Madinat Zayed Public Park in Al Dhafra and concluding at Al Jahili Park in Al Ain later this month. Each location has been transformed into vibrant activity zones with free entry but online registration encouraged to support wider public health objectives. Programming includes group exercise sessions, nutrition workshops, sleep pattern awareness installations and mental wellbeing activities, blending education with entertainment to make prevention-oriented habits more accessible.

The festival is one of the first major activations under the Healthy Living Strategy, a multi-year plan approved by His Highness Khalid bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, that aims to integrate healthier choices into everyday life for all members of society. By embedding the event within this framework, authorities are emphasising a shift from reactive healthcare to proactive prevention, seeking to reduce the long-term burden of chronic diseases through community engagement and accessible wellbeing initiatives.

Central to the strategy and the festival’s approach is the Sahatna health app, which will be used to track attendance and engagement at activities, along with metrics such as steps taken by participants. Officials have suggested that analysing these patterns could yield insights into where improvements in infrastructure or targeted interventions might be most effective, particularly in districts with higher rates of obesity or lower levels of physical activity. By linking digital health data with on-the-ground community participation, authorities aim to create a feedback loop that strengthens future public health planning.

Public and private partners have played a significant role in shaping the festival’s offerings. Strategic collaborators include PureHealth, Sakina, the Department of Municipalities and Transport, Abu Dhabi Sports Council, Modon, Al Ain Farms, Agthia, Burjeel Cancer Institute, Nestlé and AstraZeneca, among others. Community partners such as Special Olympics UAE, Active Abu Dhabi and the Department of Community Development have contributed to inclusive programming, ensuring that activities are accessible and relevant to diverse segments of the population. A broad range of sponsors and supporting entities further reinforce the event’s capacity to connect health education with tangible experiences that encourage behaviour change.

Interactive elements have been central to the festival’s appeal, with “City Moov Challenge” digital experiences and family-oriented games offering incentives to embrace physical activity and cognitive engagement. Cooking demonstrations aimed at demystifying nutrition and practical sessions on sleep hygiene seek to translate scientific guidance into everyday routines. Presenters and health educators are focusing on achievable adjustments rather than restrictive frameworks, reflecting a broader public health ethos that small, consistent changes can cumulatively improve wellbeing.

Community response has been noticeable, with families and individuals of varied age groups attending fitness sessions, mindfulness workshops and educational talks. Many visitors have highlighted the festival’s family-friendly atmosphere and the value of practical demonstrations that show how health knowledge can be applied beyond the event. For some, the festival serves as an entry point into longer-term lifestyle adjustments, with participants citing intentions to maintain routine physical activity and better sleep habits after attending.

Officials have emphasised that the festival is not a standalone effort but part of a continuum of preventive public health measures across the emirate. Throughout the year, ADPHC’s programming promotes regular health screenings, physical activity and community education as integral to reducing risk factors associated with non-communicable diseases. This aligns with global trends in public health that prioritise prevention and holistic wellbeing over episodic treatment, recognising the economic and social benefits of healthier populations.

SpaceX has signalled a major shift in its financial strategy by setting internal share prices that imply a valuation of about $800 billion and signalling plans for an initial public offering in 2026, according to communication to investors and financial institutions. The insider share sale, priced at roughly $421 per share, more than doubles the company’s valuation from mid-year levels and comes as SpaceX lays the groundwork for what could become one of the largest public market debuts ever.

Chief Financial Officer Bret Johnsen communicated to employees that the rocket and satellite operator founded by Elon Musk is preparing for a potential flotation in 2026, though the precise timing and structure remain contingent on market conditions and business milestones. SpaceX’s statement highlights that the internal valuation proposition is part of broader fundraising and liquidity arrangements rather than a definitive IPO roadmap.

Starlink, SpaceX’s satellite internet arm, underpins much of the valuation optimism. The constellation of thousands of low-Earth orbit satellites has expanded its service footprint significantly, adding millions of users globally and pushing the company’s revenue trajectory upward. Analysts say that this growth, alongside Starlink’s planned expansion into direct-to-mobile services and other connectivity niches, is central to investor enthusiasm for a public listing.

The valuation implied by the secondary offering eclipses previous private market benchmarks. SpaceX had been valued at about $400 billion earlier in 2025, and the $800-billion marker would place it among the most valuable pre-IPO companies globally. OpenAI’s valuation peak of $500 billion has been surpassed by this internal pricing, although that figure is not a public market price. SpaceX remains the second-most valuable private startup after OpenAI.

Despite speculation over the $800 billion figure, Musk has publicly questioned such valuation assertions, describing some of the media characterisations as inaccurate and emphasising the company’s strong cash flow and internal liquidity mechanisms. Musk’s comments reflect the tension between private market hype and management’s more cautious public posture on valuation and IPO timing.

SpaceX’s broader IPO strategy appears to be evolving. Reports indicate that the company has held discussions with investment banks about potentially raising over $25 billion in a 2026 offering, which could value SpaceX at more than $1 trillion. Multiple sources familiar with the talks suggest that a mid- to late-2026 timetable is under consideration, though this could shift depending on market conditions and regulatory factors.

Market participants are weighing the implications of a SpaceX public listing against broader trends in the US equity markets, which are exhibiting renewed IPO activity after a period of subdued issuance. A successful SpaceX listing at the projected scale would not only set new records in terms of funds raised but also provide a benchmark for other high-growth private companies that have been delaying public offerings.

Investors and analysts have reacted to the buildup in valuations with a mix of enthusiasm and caution. EchoStar, a significant stakeholder in SpaceX’s satellite ventures, saw its shares rise on increased IPO chatter, reflecting broader investor appetite for exposure to the commercial space sector. But concerns linger around execution risk and the technical challenges inherent in SpaceX’s ambitious projects, including the Starship launch vehicle and long-term goals such as lunar and Martian missions.

Critics of the current valuation narrative highlight that private share prices do not always translate into market realities once a company lists publicly. They note that factors such as regulatory scrutiny, evolving market sentiment and the inherent risks of aerospace and satellite operations could temper the ultimate IPO trajectory. Nonetheless, the expanded focus on Starlink’s recurring revenue streams and SpaceX’s diversified business portfolio underlines investor interest in the company’s long-term growth potential.

Danish pharmaceutical company Novo Nordisk has launched its blockbuster diabetes and weight-related therapy Ozempic in India, making the semaglutide-based injectable available across the country with a starting cost of about ₹2,200 per week for the lowest 0.25 mg dose. The move positions Ozempic as a key element in the fast-evolving metabolic health market, where type 2 diabetes and obesity rates are among the highest globally.

Available in pre-filled pens with 0.25 mg, 0.5 mg and 1 mg strengths, the therapy has been approved in India as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes. Novo Nordisk has set the monthly cost for the 0.25 mg dose at approximately ₹8,800, with incremental pricing for the higher strengths. The company says Ozempic delivers benefits beyond glycaemic control, including cardiovascular and kidney risk reduction, and supports weight management through appetite suppression.

India’s diabetes burden is among the world’s largest, with more than 100 million adults affected, according to World Health Organization estimates. Additionally, hundreds of millions live with overweight or obesity, factors that increase the risk of metabolic complications. The introduction of a globally validated therapy such as Ozempic provides clinicians with another option in managing these interconnected health challenges.

Industry analysts note that the launch comes as the country becomes a major battleground for GLP-1 receptor agonist drugs — a class that includes semaglutide and competitors such as Eli Lilly’s tirzepatide, marketed locally as Mounjaro. These therapies mimic gut hormones to regulate blood glucose and appetite, and have become focal points in efforts to curb both diabetes and excess weight.

Novo Nordisk’s roll-out follows the entry of Wegovy, its higher-dose semaglutide formulation specifically approved for chronic weight management, which debuted in India earlier in the year. Wegovy’s pricing adjustments have sparked a noticeable uptick in uptake, highlighting how cost influences adoption of these premium therapies. Ozempic’s pricing at a relatively lower weekly rate aims to broaden its accessibility, though some clinicians stress that affordability will remain a concern for patients without comprehensive insurance coverage.

The timing of the launch intersects with ongoing intellectual property developments. While the core semaglutide patent has expired in India, a secondary patent covering specific formulations remains valid until early 2026, limiting domestic generic competition. Indian courts have recently allowed local firms such as Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories to manufacture semaglutide for export to countries where Novo Nordisk holds no patent but have barred domestic sales of these versions until the formulation patent lapses, shaping competitive dynamics in the near term.

Novo Nordisk India’s managing director, Vikrant Shrotriya, has acknowledged that the weekly pricing is positioned to balance accessibility with the company’s investment in supply infrastructure. He said the goal is to expand reach beyond major urban centres to tier-1 and tier-2 cities and dedicated diabetes clinics, where consistent access to modern therapies has traditionally lagged. Clinicians emphasise that appropriate patient education and specialist referrals will be crucial in ensuring safe and effective use, given that semaglutide therapies require monitoring for gastrointestinal and metabolic effects as part of comprehensive care.

The launch also intersects with broader digital health initiatives. Local health-tech firms are partnering with international drugmakers to offer patient support programmes that provide coaching and adherence tools for individuals on GLP-1 therapies. These services aim to bolster outcomes by integrating medication with lifestyle guidance, reflecting a holistic approach to long-term metabolic health management.

Abu Dhabi has hosted the CGIAR System Council meeting for the first time in the Arabian Gulf region, marking a significant moment for global agricultural governance and underscoring the UAE’s ambition to position itself as a convening hub for food systems innovation, climate resilience and sustainable development.

The gathering brought together representatives of governments, multilateral organisations, donors and research leaders who collectively oversee CGIAR, the world’s largest public agricultural research partnership. The System Council sets strategic direction, approves funding allocations and assesses the impact of research programmes that influence food security for hundreds of millions of people, particularly in climate-vulnerable regions.

Hosting the council in the UAE reflects a broader shift in global agricultural research towards regions facing acute water stress, rising temperatures and land degradation. Officials involved in the meeting emphasised that solutions for future food systems must be designed and tested in environments that mirror the challenges many countries already face, including arid climates and fragile ecosystems. The Gulf, long associated with food import dependence, is increasingly presented as a laboratory for innovation in desert agriculture, controlled-environment farming and climate-smart technologies.

CGIAR’s research portfolio spans crop improvement, climate adaptation, nutrition, water management and biodiversity conservation. Its network includes 15 research centres operating across Africa, Asia, Latin America and parts of the Middle East. Discussions in Abu Dhabi focused on aligning research priorities with accelerating climate risks, tightening development budgets and the need to demonstrate measurable outcomes for smallholder farmers and vulnerable communities.

Senior figures attending the meeting highlighted the urgency of scaling innovations that improve productivity while reducing environmental footprints. Heat-tolerant crop varieties, drought-resilient seeds, precision irrigation systems and data-driven advisory services were cited as areas where scientific advances are already delivering tangible benefits. Council members also reviewed progress on integrating gender equity and nutrition outcomes into agricultural research, recognising that yield gains alone do not guarantee food security.

The UAE’s role as host was framed around its investments in agri-tech, food security strategies and international development partnerships. Over the past decade, the country has expanded funding for agricultural research, supported pilot projects in arid farming and strengthened ties with international institutions working on climate adaptation. Officials involved in organising the meeting said the decision to host the council aligned with national priorities on sustainable food production and knowledge-based economic diversification.

Beyond symbolism, the location influenced the agenda. Sessions examined how lessons from desert agriculture can be adapted for other water-scarce regions, including parts of Africa and Central Asia. Controlled-environment agriculture, including greenhouse and vertical farming, featured prominently as participants assessed their potential to complement open-field farming rather than replace it. Energy use, affordability and scalability in lower-income settings were central to these debates.

Financing emerged as a critical issue. CGIAR operates in an environment of competing global crises, where humanitarian needs, climate finance and development assistance all draw from limited public funds. Council members discussed strategies to broaden the donor base, attract blended finance and strengthen partnerships with the private sector without compromising CGIAR’s public-good mandate. Transparency, accountability and rigorous impact evaluation were repeatedly emphasised as essential to maintaining donor confidence.

The meeting also addressed governance reforms within CGIAR, which has undergone structural changes aimed at improving coordination across its research centres. Council members reviewed progress on streamlining programmes, reducing duplication and enhancing collaboration with national research systems. Strengthening ties with regional institutions in the Middle East and North Africa was identified as an opportunity to expand the reach of research outputs while respecting local contexts.